In the curative-intent unresectable Stage 3 NSCLC setting, effective multidisciplinary care can help improve outcomes1-3

 
0

~20% of patients presenting with Stage 3 NSCLC to a primary care provider or pulmonologist never receive care from other multidisciplinary team members, including oncologists4

  • Referral to a medical oncologist can increase the likelihood of patients receiving appropriate and timely treatment, which has been associated with improved survival rates5,6
  • Collective input of a multidisciplinary team is essential for accurate staging and appropriate treatment selection in Stage 3 NSCLC7

Patient Referral From PCPs and Pulmonologists to an Oncologist May Provide the Best Opportunity for Optimal Treatment of Unresectable Stage 3 NSCLC

Make sure that patients are referred…Get them in the door to the medical oncologist and radiation oncologist so we can provide the best care.

–Dr Jhanelle Gray*

20% of patients with early-stage NSCLC were found to be understaged, potentially leading to suboptimal treatment decisions

In one study (N=75), 20% of patients with early-stage NSCLC were found to be understaged, potentially leading to suboptimal treatment decisions.10,11†

  • Patients seen by a multidisciplinary team are more likely to receive standard of care treatment for Stage 3 NSCLC8
  • For patients accurately staged with unresectable Stage 3 NSCLC, the standard of care is curative intent concurrent chemoradiotherapy9

Accurate Staging of NSCLC Is Critical

If we’re not able to stage our patients, we could be undertreating them, overtreating them.

–Dr Victoria Villaflor*

Accurate diagnosis and staging may increase the likelihood of:
  • Referral to an oncologist12
  • Appropriate treatment selection5
  • Timely treatment initiation, which has been shown to significantly improve survival rates6

NSCLC=non-small cell lung cancer; CRT=chemoradiotherapy; PCP=primary care provider.

*The views and opinions expressed in the Art of CRT video series are those of the individual panel members and do not represent the views or opinions of AstraZeneca. These videos contain anecdotal information gathered from a discussion with 8 physicians and nurses based on their opinions/experiences. Recommendations are general and may vary with patients.

Patients underwent staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

References: 1. Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019;26(1):37-42. 2. Detterbeck FC, Boffa DJ, Kim AW Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193-203. 3. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155. 4. Data on file, US-25141. AstraZeneca Pharmaceuticals LP; 2018. 5. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151(4):221-228. 6. Kasymjanova G, Small D, Cohen V, et al. Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes. Curr Oncol. 2017;24(5):302-309. 7. Majem M, Hernandez-Hernandez J, Hernando-Trancho F, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clin Transl Oncol. 2020;22(1):21-36. 8. Bobbili P, Ryan K, Duh MS, DerSarkissian M, Yee CW, Gomez JE. Specialist visit patterns and overall survival by type of therapy among patients with unresectable stage III non-small cell lung cancer. Int J Rad Oncol. 2019;105(1):E498. 9. Moore S, Leung B, Wu J, Ho C. Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy. J Thorac Oncol. 2019;14(8):1430-1439. 10. Farjah F, Flum DR, Ramsey SD, Heagerty PJ, Symons RG, Wood DE. Multi-modality mediastinal staging for lung cancer among Medicare beneficiaries. J Thorac Oncol. 2009;4(3):355-363. 11. Vial MR, O’Connell OJ, Grosu HB, et al. Diagnostic performance of endobronchial ultrasound-guided mediastinal lymph node sampling in early stage non-small cell lung cancer: a prospective study. Respirology. 2018;23(1):76-81. 12. Goulart BHL, Reyes CM, Fedorenko CR, et al. Referral and treatment patterns among patients with stage III and IV non–small-cell lung cancer. J Oncol Pract. 2013:9(1):42-50.